Successful treatment with oseltamivir phosphate in children with ITP who failed first-line therapy: a case series report

• Published in: Annals of hematology Vol. 103; no. 2; pp. 405 - 408
• Main Authors: Liu, Li-ya, Zhang, Bo, Song, Chun-dong, Li, Peng-fei, Yang, Meng, Ren, Xian-qing, Ding, Ying
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2024; Springer Nature B.V
• Subjects: Antibodies; Blood Platelets; Bone marrow; Child; Children & youth; Chinese medicine; Drug dosages; Hematology; Hospitals; Humans; Hyperplasia; Immunoglobulins; Infectious diseases; Influenza; Liver; Medicine; Medicine & Public Health; Oncology; Oral administration; Original Article; Oseltamivir - therapeutic use; Pathogens; Phosphates; Platelet Count; Purpura, Thrombocytopenic, Idiopathic - drug therapy; Thrombocytopenia; Thrombocytopenia - therapy; Oseltamivir phosphate; Children; Immune thrombocytopenia
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-023-05581-z

Immune thrombocytopenia (ITP) is a common bleeding disorder in children. First-line medicines (glucocorticoids and immunoglobulin) may not be effective for some children, endangering their lives, posing challenges for healthcare facilities, and leading to an unfavorable prognosis. As a sialidase inhibitor, oseltamivir phosphate can reduce the destruction of platelets in liver macrophages by inhibiting the sialylation of platelets, and finally achieve the purpose of increasing platelet count. In this paper, three cases of children with ITP who failed first-line therapy and were cured by oral administration of oseltamivir phosphate granules were reported. The mechanism of action of oseltamivir phosphate granules was clarified.